Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017

被引：15
|
作者：
Frank I. Scott
Gary R. Lichtenstein
机构：
[1] University of Colorado Anschutz Medical Campus,Crohn’s and Colitis Center, Division of Gastroenterology and Hepatology
[2] Perelman School of Medicine,Gastroenterology Division
[3] University of Pennsylvania,undefined
来源：
Current Treatment Options in Gastroenterology | 2018年 / 16卷 / 1期
关键词：
Biosimilars; Indication extrapolation; Interchangeability; Infliximab; Adalimumab; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis;
D O I：
10.1007/s11938-018-0177-z
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：147 / 164
页数：17
相关论文
共 50 条
  • [41] Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN
    de Ridder, Lissy
    Assa, Amit
    Bronsky, Jiri
    Romano, Claudio
    Russell, Richard K.
    Afzal, Nadeem A.
    Hauer, Almuthe C.
    Knafelz, Daniela
    Lionetti, Paolo
    Strisciuglio, Caterina
    Veres, Gabor
    Winter, Harland
    Wolters, Victorien M.
    Sladek, Malgorzata
    Vulto, Arnold G.
    Dias, Jorge A.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2019, 68 (01) : 144 - 153
  • [42] What is the evidence for the use of probiotics in the treatment of inflammatory bowel disease?
    Cary, Virginia A.
    Boullata, Joseph
    JOURNAL OF CLINICAL NURSING, 2010, 19 (7-8) : 904 - 916
  • [43] Must immunomodulators be added to biological treatment in inflammatory bowel disease?
    Gomollon, Fernando
    Gisbert, Javier P.
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2010, 33 (01): : 43 - 53
  • [44] Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
    Petric, Zvonimir
    Goncalves, Joao
    Paixao, Paulo
    PHARMACEUTICS, 2022, 14 (09)
  • [45] Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile
    Danese, Silvio
    Fiorino, Gionata
    CURRENT MEDICINAL CHEMISTRY, 2019, 26 (02) : 280 - 287
  • [46] Treatment of Extraintestinal Manifestations in Inflammatory Bowel Disease
    Lakatos, Peter L.
    Lakatos, Laszlo
    Kiss, Lajos S.
    Peyrin-Biroulet, Laurent
    Schoepfer, Alain
    Vavricka, Stephan
    DIGESTION, 2012, 86 : 28 - 35
  • [47] Pharmacogenetics of inflammatory bowel disease
    Katsanos, Konstantinos H.
    Papadakis, Konstantinos A.
    PHARMACOGENOMICS, 2014, 15 (16) : 2049 - 2062
  • [48] Transplacental Transfer of Immunosuppressants and Biologics Used for the Treatment of Inflammatory Bowel Disease
    Chaparro, Maria
    Gisbert, Javier P.
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2011, 12 (05) : 765 - 773
  • [49] Treatment to target in patients with inflammatory bowel disease. What is the evidence?
    Frimor, Camilla
    Kjeldsen, Jens
    Ainsworth, Mark
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2020, 55 (05) : 528 - 536
  • [50] Acne treatment and inflammatory bowel disease: What is the evidence?
    Alikhan, Ali
    Henderson, Gregory P.
    Becker, Lauren
    Sciallis, Gabriel F.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 65 (03) : 650 - 654
12345